XASX
ALA
Market cap80mUSD
Aug 01, Last price
0.11AUD
1D
7.14%
1Q
19.32%
IPO
238.71%
Name
Arovella Therapeutics Ltd
Chart & Performance
P/E
—
P/S
7,341.17
EPS
—
Div Yield, %
—
Shrs. gr., 5y
51.91%
Rev. gr., 5y
-57.45%
Revenues
17k
-95.81%
Net income
-9m
L-14.10%
CFO
-7m
L+8.07%
Earnings
Aug 18, 2025
Profile
Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer and conditions that affect the central nervous system in Australia and internationally. Its product pipeline includes ZolpiMist, an oral spray of zolpidem tartrate to treat short-term insomnia, which is marketed under the brand name of Ambien or Stilnox; invariant natural killer T (iNKT), a cell therapy platform to treat blood cancer; OroMist, an oro-mucosal technology that delivers a range of drug classes through the cheeks, gums, tongue, or floor of the mouth; and Anagrelide to treat cancer. The company also develops oral sprays to treat migraine headaches, motion sickness, and drug-resistant epilepsy. It has a collaborative research agreement with Imperial College London. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is headquartered in Osborne Park, Australia.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | 2016‑06 | |
| Income | |||||||||
Revenues | 17 -95.81% | 406 37.22% | |||||||
Cost of revenue | 10,828 | 10,927 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (10,811) | (10,521) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (1,049) | ||||||||
Tax Rate | |||||||||
NOPAT | (10,811) | (9,472) | |||||||
Net income | (8,746) -14.10% | (10,181) 18.11% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 14,609 | 5,478 | |||||||
BB yield | -11.08% | -15.40% | |||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | 16 | ||||||||
Net debt | (12,714) | (5,175) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (6,914) | (6,398) | |||||||
CAPEX | (129) | (3) | |||||||
Cash from investing activities | (179) | 95 | |||||||
Cash from financing activities | 14,609 | 5,407 | |||||||
FCF | (10,893) | (9,151) | |||||||
| Balance | |||||||||
Cash | 12,714 | 5,175 | |||||||
Long term investments | |||||||||
Excess cash | 12,714 | 5,155 | |||||||
Stockholders' equity | 11,228 | 3,780 | |||||||
Invested Capital | 16 | 9 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 941,423 | 711,483 | |||||||
Price | 0.14 180.00% | 0.05 | |||||||
Market cap | 131,799 270.49% | 35,574 | |||||||
EV | 119,085 | 30,399 | |||||||
EBITDA | (10,768) | (9,684) | |||||||
EV/EBITDA | |||||||||
Interest | 9 | 21 | |||||||
Interest/NOPBT | |||||||||